Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11504132 | 0.81 | GRIN2D (0.30) | GRIN1GRIN2B | |
| SCHEMBL3189599 | 0.81 | GRIN2D (0.40) | CA12CA9KMT2ACYP2C19APEX1 | |
| SCHEMBL11504221 | 0.73 | GRIN2D (0.36) | CA12CA1CA2CA9CYP2C19 | |
| SCHEMBL11503769 | 0.69 | ALDH1A1 (0.39) | TSHRCYP2C19HPGDGRIN1GRIN2B | |
| SCHEMBL13953033 | 0.69 | GRIA1 (0.39) | KMT2ATSHRBLMGRIN1GRIN2B | |
| SCHEMBL4960220 | 0.68 | CA12 (0.42) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL4602946 | 0.65 | CA12 (0.51) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL18634058 | 0.65 | GRIN2D (0.34) | GRIN1GRIN2B | |
| SCHEMBL10205165 | 0.64 | TSHR (0.34) | TSHRCYP2C19TDP1 | |
| SCHEMBL27033921 | 0.63 | LMNA (0.47) | KMT2ARAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0525057-B1 | ANTIMICROBIAL QUINOLONYL LACTAMS | PROCTER & GAMBLE PHARMA (US) | 2000-06-14 | — | — | EP | claimed |
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| EP-0366641-B1 | Novel antimicrobial quinolonyl lactam esters | NORWICH EATON PHARMA (US) | 2000-07-05 | — | — | EP | disclosed |
| EP-0525057-B1 | ANTIMICROBIAL QUINOLONYL LACTAMS | PROCTER & GAMBLE PHARMA (US) | 2000-06-14 | — | — | EP | disclosed |
| EP-0997466-A1 | Novel antimicrobial lactam-quinolones | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 2000-05-03 | — | — | EP | disclosed |
| EP-0775114-B1 | PROCESS FOR MAKING ANTIMICROBIAL COMPOUNDS | PROCTER & GAMBLE (US) | 2000-03-22 | — | — | EP | disclosed |
| US-5801242-A | Process for making quinolonyl lactam antimicrobials and novel intermediate compounds | THE PROCTER & GAMBLE COMPANY (US) | 1998-09-01 | — | — | US | disclosed |
| WO-1991016327-A1 | ANTIMICROBIAL QUINOLONYL LACTAMS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1991-10-31 | — | — | WO | disclosed |
| WO-1990004594-A1 | NOVEL ANTIMICROBIAL QUINOLONYL LACTAM ESTERS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1990-05-03 | — | — | WO | disclosed |
| WO-1990004595-A1 | NOVEL ANTIMICROBIAL FLUOROQUINOLONYL CEPHEMS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1990-05-03 | — | — | WO | disclosed |
| EP-0366193-A2 | Novel antimicrobial quinolonyl lactams | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0366641-A2 | Novel antimicrobial quinolonyl lactam esters | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0366640-A2 | Novel antimicrobial fluoroquinolonyl cephems | Norwich-Eaton Pharmaceuticals, Inc. (US) | 1990-05-02 | — | — | EP | disclosed |
| EP-0366189-A2 | Novel antimicrobial lactam-quinolones | Norwich Eaton Pharmaceuticals, Inc. (US) | 1990-05-02 | — | — | EP | disclosed |
| WO-1990000170-A1 | NOVEL 6-AMIDO-1-METHYLCARBAPENEMS | MERCK & CO., INC. (US) | 1990-01-11 | — | — | WO | disclosed |
| EP-0350211-A2 | Novel 6-amido-1-methyl carbapenems | MERCK & CO. INC. (US) | 1990-01-10 | — | — | EP | disclosed |
| EP-0187500-A1 | Monobactams | THE UPJOHN COMPANY (US) | 1986-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | CA12 3130/4885CA1 3675/4885CA2 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.